Levofloxacin sodium | CAS#872606-49-0 | fluoroquinolone

MedKoo Cat#: 598725 | Name: Levofloxacin sodium

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Levofloxacin sodium is a synthetic fluoroquinolone (FLUOROQUINOLONES) antibacterial agent that inhibits the supercoiling activity of bacterial DNA GYRASE, halting DNA REPLICATION.

Chemical Structure

Levofloxacin sodium

CAS#872606-49-0

Theoretical Analysis

MedKoo Cat#: 598725

Name: Levofloxacin sodium

CAS#: 872606-49-0

Chemical Formula: C18H19FN3NaO4

Exact Mass:

Molecular Weight: 383.36

Elemental Analysis: C, 56.40; H, 5.00; F, 4.96; N, 10.96; Na, 6.00; O, 16.69

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

Levofloxacin sodium;

IUPAC/Chemical Name

sodium (S)-9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylate

InChi Key

NCGMIBYQHQSCGQ-PPHPATTJSA-M

InChi Code

InChI=1S/C18H20FN3O4.Na/c1-10-9-26-17-14-11(16(23)12(18(24)25)8-22(10)14)7-13(19)15(17)21-5-3-20(2)4-6-21;/h7-8,10H,3-6,9H2,1-2H3,(H,24,25);/q;+1/p-1/t10-;/m0./s1

SMILES Code

O=C(C(C1=O)=CN2[C@@H](C)COC3=C(N4CCN(C)CC4)C(F)=CC1=C23)[O-].[Na+]

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.03.00

More Info

Product Data

Product Data

Instruction

View handling instruction

Biological target:

Levofloxacin ((-)-Ofloxacin) sodium is an orally active antibiotic and is active against both Gram-positive and Gram-negative bacteria. Levofloxacin sodium inhibits the DNA gyrase and topoisomerase IV.

In vitro activity:

Levofloxacin exhibited twofold greater inhibitory and bactericidal activities than ofloxacin against either extracellular or intracellular tubercle bacilli. Reference: Antimicrob Agents Chemother. 1994 May;38(5):1161-4. https://pubmed.ncbi.nlm.nih.gov/8067756/

In vivo activity:

This study investigated the toxic effect of levofloxacin (LVFX), a quinolone antibacterial agent, on cartilage by examining aspects of its in vivo toxicokinetics and effect on the function of cultured chondrocytes of the femoral articular cartilage from juvenile New Zealand White rabbits. Repeated administration of LVFX (100 mg/kg) orally for 7 days induced focal necrosis and superficial erosion in the articular cartilage of the femoral condyle, but 30 mg/kg did not. Reference: Antimicrob Agents Chemother. 1995 Sep;39(9):1979-83. https://pubmed.ncbi.nlm.nih.gov/8540702/

Preparing Stock Solutions

The following data is based on the product molecular weight 383.36 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Mor N, Vanderkolk J, Heifets L. Inhibitory and bactericidal activities of levofloxacin against Mycobacterium tuberculosis in vitro and in human macrophages. Antimicrob Agents Chemother. 1994 May;38(5):1161-4. doi: 10.1128/AAC.38.5.1161. PMID: 8067756; PMCID: PMC188169. 2. Fu KP, Lafredo SC, Foleno B, Isaacson DM, Barrett JF, Tobia AJ, Rosenthale ME. In vitro and in vivo antibacterial activities of levofloxacin (l-ofloxacin), an optically active ofloxacin. Antimicrob Agents Chemother. 1992 Apr;36(4):860-6. doi: 10.1128/AAC.36.4.860. Erratum in: Antimicrob Agents Chemother 1992 Aug;36(8):1797. PMID: 1503449; PMCID: PMC189464. 3. Kato M, Takada S, Ogawara S, Takayama S. Effect of levofloxacin on glycosaminoglycan and DNA synthesis of cultured rabbit chondrocytes at concentrations inducing cartilage lesions in vivo. Antimicrob Agents Chemother. 1995 Sep;39(9):1979-83. doi: 10.1128/AAC.39.9.1979. PMID: 8540702; PMCID: PMC162867. 4. JI B, Lounis N, Truffot-Pernot C, Grosset J. In vitro and in vivo activities of levofloxacin against Mycobacterium tuberculosis. Antimicrob Agents Chemother. 1995 Jun;39(6):1341-4. doi: 10.1128/AAC.39.6.1341. PMID: 7574527; PMCID: PMC162738.

In vitro protocol:

In vivo protocol:

1. Kato M, Takada S, Ogawara S, Takayama S. Effect of levofloxacin on glycosaminoglycan and DNA synthesis of cultured rabbit chondrocytes at concentrations inducing cartilage lesions in vivo. Antimicrob Agents Chemother. 1995 Sep;39(9):1979-83. doi: 10.1128/AAC.39.9.1979. PMID: 8540702; PMCID: PMC162867. 2. JI B, Lounis N, Truffot-Pernot C, Grosset J. In vitro and in vivo activities of levofloxacin against Mycobacterium tuberculosis. Antimicrob Agents Chemother. 1995 Jun;39(6):1341-4. doi: 10.1128/AAC.39.6.1341. PMID: 7574527; PMCID: PMC162738.

1: Fayyaz M, Yousuf RI, Shoaib MH, Ali T, Nasiri I, Ashraf N. Quality evaluation and in vitro interaction studies between levofloxacin 250mg and diclofenac sodium 50mg tablets. Pak J Pharm Sci. 2015 Jan;28(1):119-28. PubMed PMID: 25553690. 2: Türkeş C, Söyüt H, Beydemir Ş. Human serum paraoxonase-1 (hPON1): in vitro inhibition effects of moxifloxacin hydrochloride, levofloxacin hemihidrate, cefepime hydrochloride, cefotaxime sodium and ceftizoxime sodium. J Enzyme Inhib Med Chem. 2015;30(4):622-8. doi: 10.3109/14756366.2014.959511. Epub 2014 Dec 18. PubMed PMID: 25519764. 3: Sun H, Wang H, Ge X. Simultaneous determination of the combined drugs of ceftriaxone sodium, metronidazole, and levofloxacin in human urine by high-performance liquid chromatography. J Clin Lab Anal. 2012 Nov;26(6):486-92. doi: 10.1002/jcla.21551. PubMed PMID: 23143633. 4: Fleischbein E, Montgomery PA, Zhou CS. Visual compatibility of micafungin sodium and levofloxacin injections. Am J Health Syst Pharm. 2012 Dec 15;69(24):2130. doi: 10.2146/ajhp120484. PubMed PMID: 23230033. 5: El Najjar NH, Deborde M, Journel R, Vel Leitner NK. Aqueous chlorination of levofloxacin: kinetic and mechanistic study, transformation product identification and toxicity. Water Res. 2013 Jan 1;47(1):121-9. doi: 10.1016/j.watres.2012.09.035. Epub 2012 Oct 4. PubMed PMID: 23084340. 6: Shao J, Cheng H, Wang C, Wang Y. A phytoanticipin derivative, sodium houttuyfonate, induces in vitro synergistic effects with levofloxacin against biofilm formation by Pseudomonas aeruginosa. Molecules. 2012 Sep 20;17(9):11242-54. PubMed PMID: 22996347. 7: Lin T, Gong L. Sodium hyaluronate eye drops treatment for superficial corneal abrasion caused by mechanical damage: a randomized clinical trial in the People's Republic of China. Drug Des Devel Ther. 2015 Jan 30;9:687-94. doi: 10.2147/DDDT.S77270. eCollection 2015. PubMed PMID: 25678773; PubMed Central PMCID: PMC4322606. 8: El-Zahaby SA, Kassem AA, El-Kamel AH. Formulation and in vitro evaluation of size expanding gastro-retentive systems of levofloxacin hemihydrate. Int J Pharm. 2014 Apr 10;464(1-2):10-8. doi: 10.1016/j.ijpharm.2014.01.024. Epub 2014 Jan 26. PubMed PMID: 24472642. 9: Chung TC, Li CT, Kou HS, Wu HL. High-Performance Liquid Chromatographic Analysis of Sarcosine as a Fluorescent Levofloxacin Derivative. J Chromatogr Sci. 2015 Sep;53(8):1310-5. doi: 10.1093/chromsci/bmv010. Epub 2015 Feb 16. PubMed PMID: 25688037. 10: Fiel SB. Aerosolized antibiotics in cystic fibrosis: an update. Expert Rev Respir Med. 2014 Jun;8(3):305-14. doi: 10.1586/17476348.2014.896205. Review. PubMed PMID: 24838090. 11: Helmy SA. Simultaneous quantification of linezolid, tinidazole, norfloxacin, moxifloxacin, levofloxacin, and gatifloxacin in human plasma for therapeutic drug monitoring and pharmacokinetic studies in human volunteers. Ther Drug Monit. 2013 Dec;35(6):770-7. doi: 10.1097/FTD.0b013e318297b6b0. PubMed PMID: 24061442. 12: Salem AA, Mossa HA. Method validation and determinations of levofloxacin, metronidazole and sulfamethoxazole in an aqueous pharmaceutical, urine and blood plasma samples using quantitative nuclear magnetic resonance spectrometry. Talanta. 2012 Jan 15;88:104-14. doi: 10.1016/j.talanta.2011.10.016. Epub 2011 Oct 25. PubMed PMID: 22265475. 13: Miyake T, Ito N, Tajima K, Goto H, Furukawa T. Comparison of moxifloxacin and levofloxacin in an epithelial disorder model using cultured rabbit corneal epithelial cell sheets. Graefes Arch Clin Exp Ophthalmol. 2012 Jul;250(7):1035-41. doi: 10.1007/s00417-011-1916-1. Epub 2012 Jan 27. PubMed PMID: 22282216. 14: Mizuki N, Watanabe Y, Miyamoto M, Iijima Y, Takiyama N, Ito Y, Ito N, Nishida T, Iwata S, Endo Y, Ito D. Flomoxef sodium and levofloxacin concentrations in aqueous humor. Ocul Immunol Inflamm. 2005 Apr-Jun;13(2-3):229-34. PubMed PMID: 16019684. 15: Baig MS, Ahad A, Aslam M, Imam SS, Aqil M, Ali A. Application of Box-Behnken design for preparation of levofloxacin-loaded stearic acid solid lipid nanoparticles for ocular delivery: Optimization, in vitro release, ocular tolerance, and antibacterial activity. Int J Biol Macromol. 2016 Apr;85:258-70. doi: 10.1016/j.ijbiomac.2015.12.077. Epub 2015 Dec 29. PubMed PMID: 26740466. 16: Gupta H, Aqil M, Khar RK, Ali A, Bhatnagar A, Mittal G. An alternative in situ gel-formulation of levofloxacin eye drops for prolong ocular retention. J Pharm Bioallied Sci. 2015 Jan-Mar;7(1):9-14. doi: 10.4103/0975-7406.149810. PubMed PMID: 25709330; PubMed Central PMCID: PMC4333635. 17: Wang C, Wang J, Deng L. Evaluating interaction forces between BSA and rabbit anti-BSA in sulphathiazole sodium, tylosin and levofloxacin solution by AFM. Nanoscale Res Lett. 2011 Nov 3;6(1):579. doi: 10.1186/1556-276X-6-579. PubMed PMID: 22053876; PubMed Central PMCID: PMC3245524. 18: Siafaka PI, Zisi AP, Exindari MK, Karantas ID, Bikiaris DN. Porous dressings of modified chitosan with poly(2-hydroxyethyl acrylate) for topical wound delivery of levofloxacin. Carbohydr Polym. 2016 Jun 5;143:90-9. doi: 10.1016/j.carbpol.2016.02.009. Epub 2016 Feb 4. PubMed PMID: 27083347. 19: Maeda T, Takahashi K, Ohtsu N, Oguma T, Ohnishi T, Atsumi R, Tamai I. Identification of influx transporter for the quinolone antibacterial agent levofloxacin. Mol Pharm. 2007 Jan-Feb;4(1):85-94. PubMed PMID: 17274666. 20: Maraki S, Lionakis S, Ntaoukakis M, Barbounakis E, Ntasis E, Kofteridis DP, Samonis G. Effects of levofloxacin, moxifloxacin and prulifloxacin on murine gut colonization by Candida albicans. Med Mycol. 2011 May;49(4):419-23. doi: 10.3109/13693786.2010.538443. Epub 2010 Nov 26. PubMed PMID: 21108571.